[go: up one dir, main page]

UA117216C2 - Пухлиноасоційований пептид та його застосування - Google Patents

Пухлиноасоційований пептид та його застосування

Info

Publication number
UA117216C2
UA117216C2 UAA201302331A UAA201302331A UA117216C2 UA 117216 C2 UA117216 C2 UA 117216C2 UA A201302331 A UAA201302331 A UA A201302331A UA A201302331 A UAA201302331 A UA A201302331A UA 117216 C2 UA117216 C2 UA 117216C2
Authority
UA
Ukraine
Prior art keywords
peptide
application
tumor associated
cytotoxic
associated peptide
Prior art date
Application number
UAA201302331A
Other languages
English (en)
Inventor
Зінгх Харпреет
Шор Олівер
Траутвайн Клаудія
Хільф Норберт
Вайншенк Тоні
Вальтер Штеффен
Левандровскі Петер
Original Assignee
Імматікс Біотекнолоджіс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Імматікс Біотекнолоджіс Гмбх filed Critical Імматікс Біотекнолоджіс Гмбх
Publication of UA117216C2 publication Critical patent/UA117216C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід стосується пептиду, який має здатність зв'язуватися з молекулою головного комплексу гістосумісності людини (МНС) класу ІІ, нуклеїнової кислоти, вектора експресії, клітини-хазяїна, способу in vitro продукування активованих цитотоксичних Т-лімфоцитів шляхом застосування зазначеного пептиду, активованого цитотоксичного Т-лімфоциту, отриманого відповідно до зазначеного способу, та застосування пептиду, вектора експресії, клітини-хазяїна або активованого цитотоксичного Т-лімфоциту як лікарського засобу для лікування раку.
UAA201302331A 2007-07-27 2008-07-25 Пухлиноасоційований пептид та його застосування UA117216C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014796 2007-07-27
US95310907P 2007-07-31 2007-07-31
US98124107P 2007-10-19 2007-10-19
UAA201001960A UA103882C2 (uk) 2007-07-27 2008-07-25 Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина

Publications (1)

Publication Number Publication Date
UA117216C2 true UA117216C2 (uk) 2018-07-10

Family

ID=39926464

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201302331A UA117216C2 (uk) 2007-07-27 2008-07-25 Пухлиноасоційований пептид та його застосування
UAA201001960A UA103882C2 (uk) 2007-07-27 2008-07-25 Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201001960A UA103882C2 (uk) 2007-07-27 2008-07-25 Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина

Country Status (20)

Country Link
US (1) US7994276B2 (uk)
EP (2) EP2567707B1 (uk)
JP (2) JP5352586B2 (uk)
KR (1) KR101167392B1 (uk)
CN (2) CN101765434B (uk)
AU (1) AU2008281013B2 (uk)
BR (1) BRPI0814140A2 (uk)
CA (2) CA2694771A1 (uk)
DK (1) DK2567707T3 (uk)
EA (2) EA018457B1 (uk)
ES (1) ES2608583T3 (uk)
HU (1) HUE032379T2 (uk)
LT (1) LT2567707T (uk)
MX (1) MX2010001088A (uk)
NZ (1) NZ582823A (uk)
PL (1) PL2567707T3 (uk)
PT (1) PT2567707T (uk)
SI (1) SI2567707T1 (uk)
UA (2) UA117216C2 (uk)
WO (1) WO2009015841A1 (uk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
MX355759B (es) * 2011-10-28 2018-04-27 Oncotherapy Science Inc Peptidos topk y vacunas que incluyen los mismos.
AU2013259598B2 (en) * 2012-05-08 2018-10-04 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
CA2974237C (en) 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN105586312A (zh) * 2016-02-29 2016-05-18 时宏珍 Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
EP3518956A1 (en) * 2016-09-27 2019-08-07 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CA3058393A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
EP3609530A1 (en) * 2017-04-10 2020-02-19 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
AU2018253341B2 (en) * 2017-04-10 2022-01-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR102905054B1 (ko) 2017-11-22 2025-12-29 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
AU2020320445A1 (en) * 2019-07-30 2022-03-03 University Health Network T cell receptors and methods of use thereof
JP2023507347A (ja) * 2019-12-18 2023-02-22 エヴァクシオン・バイオテック・アクティエセルスカブ ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種
CN111363009B (zh) * 2020-03-18 2020-10-30 北京鼎成肽源生物技术有限公司 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP4291508B2 (ja) 1997-10-10 2009-07-08 アメリカ合衆国 癌胎児性抗原（ｃｅａ）のアゴニストおよびアンタゴニストペプチド
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6623923B1 (en) * 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU7721500A (en) * 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030017167A1 (en) * 2000-06-09 2003-01-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2411278A1 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020102544A1 (en) * 2000-09-15 2002-08-01 David Mack Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
CA2431313A1 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2005536987A (ja) * 2002-04-01 2005-12-08 ユーロ−セルティーク エス．エイ． 抗原提示細胞標的化機構を含むエピトープ構築物
US20030211477A1 (en) * 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2004014867A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20040265230A1 (en) * 2003-01-06 2004-12-30 Martinez Robert Vincent Compositions and methods for diagnosing and treating colon cancers
JP2007523610A (ja) * 2003-05-05 2007-08-23 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 癌胎児抗原をコードする合成遺伝子およびその使用
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
WO2006027693A2 (en) * 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
ITRM20050064A1 (it) * 2005-02-16 2006-08-17 Univ Siena Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
ES2367643T3 (es) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
ES2341295T3 (es) 2005-09-05 2010-06-17 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
EP1988901B1 (en) * 2006-02-27 2020-01-29 Gal Markel Ceacam based antibacterial agents
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane

Also Published As

Publication number Publication date
AU2008281013B2 (en) 2012-06-28
PT2567707T (pt) 2016-12-27
NZ582823A (en) 2012-04-27
EP2567707B1 (en) 2016-10-05
JP2013165721A (ja) 2013-08-29
DK2567707T3 (en) 2017-07-31
LT2567707T (lt) 2017-01-10
AU2008281013A1 (en) 2009-02-05
CA2817054A1 (en) 2009-02-05
EA201000208A1 (ru) 2011-02-28
US7994276B2 (en) 2011-08-09
EA201300322A1 (ru) 2013-10-30
EP2567707A2 (en) 2013-03-13
US20090148400A1 (en) 2009-06-11
CN103360466A (zh) 2013-10-23
CA2817054C (en) 2017-02-28
JP5746251B2 (ja) 2015-07-08
JP2010534627A (ja) 2010-11-11
ES2608583T3 (es) 2017-04-12
CN101765434B (zh) 2014-12-17
AU2008281013A2 (en) 2010-04-29
JP5352586B2 (ja) 2013-11-27
EA023928B1 (ru) 2016-07-29
HK1182923A1 (en) 2013-12-13
KR101167392B1 (ko) 2012-07-19
WO2009015841A1 (en) 2009-02-05
UA103882C2 (uk) 2013-12-10
PL2567707T3 (pl) 2017-03-31
MX2010001088A (es) 2010-06-01
BRPI0814140A2 (pt) 2017-03-28
EP2178557A1 (en) 2010-04-28
CN103360466B (zh) 2016-08-03
CA2694771A1 (en) 2009-02-05
SI2567707T1 (sl) 2017-01-31
KR20100040875A (ko) 2010-04-21
CN101765434A (zh) 2010-06-30
EA018457B1 (ru) 2013-08-30
EP2178557B1 (en) 2017-03-01
HUE032379T2 (en) 2017-09-28
EP2567707A3 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
UA113712C2 (xx) Антитіло до fap і способи його застосування
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
UA98295C2 (uk) Пухлино-асоційований пептид, що неспецифічно зв'язується з молекулами ii класу лейкоцитарного антигену людини (hla)
UA103751C2 (uk) Імуногенний пептид для імунотерапії
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MY158219A (en) Method for activation of helper t cell and composition for use in the method
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
WO2012044999A3 (en) Reversible protein multimers, methods for their production and use
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MX2014009628A (es) Uniones a cdim y sus usos.
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
WO2010132389A3 (en) Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA200870615A1 (ru) Производные лептомицина
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
PH12012501545B1 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins
TN2009000194A1 (en) Novel antiproliferation antibodies